Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
Hiro

47results about How to "Improve cell adhesion" patented technology

Medical devices comprising porous layers for the release of therapeutic agents

In accordance with an aspect of the invention, implantable or insertable medical devices are provided in which a porous layer is disposed over a therapeutic-agent-containing region. In accordance with another aspect of the invention, medical devices are fabricated by a method in which a porous layer is deposited over a therapeutic-agent-containing region using a field-injection-based electrospray technique.
Owner:BOSTON SCI SCIMED INC

Microgels for Encapsulation of Cells and Other Biologic Agents

Methods of encapsulating cargo in a microgel droplet, microgel droplets prepared according the provided methods, and methods of use thereof are disclosed. The methods of preparing cargo-encapsulated microgels generally include flowing through a flow-focusing nozzle of a microfluidic device a macromer phase, an oil phase, and a crosslinker phase to form microgel droplets by oil-water emulsion. The phases are pumped, injected, or flowed through the microfluidic device such that as the macromer phase approaches the flow focusing nozzle, the co-flowing oil phase shields the macromer from contact with the crosslinker phase until flow instability occurs and macromer phase droplets form. After flow instability occurs, the crosslinker diffuses from the crosslinker phase into the droplets in an effective amount to covalently crosslink the macromer into a microgel network encapsulating the cargo in the crosslinked macromer. Microgels prepared according to the disclosed methods and methods of use thereof are also provided.
Owner:GEORGIA TECH RES CORP

Non-covalent inhibitors of urokinase and blood vessel formation

Novel compounds having activity as non-covalent inhibitors of urokinase and having activity in reducing or inhibiting blood vessel formation are provided. These compounds have Pi a group having an amidino or guanidino moiety or derivative thereof. These compounds are useful in vitro for monitoring plasminogen activator levels and in vivo in treatment of conditions which are ameliorated by inhibition of or decreased activity of urokinase and in treating pathologic conditions wherein blood vessel formation is related to a pathologic condition.
Owner:KEVIN S HELMBACHER GENERAL COUNSEL +1

Methods of surface modification of a flexible substrate to enhance cell adhesion

The present invention provides methods of producing a surface with enhanced cell-adhesive properties comprising applying a stress to a polymeric matrix. The strained matrix is then modified by grafting a self-assembled monolayer onto the strained matrix, with the self-assembled monolayer comprising at least one exposed functional group. At least one cell-adhesive molecule can then be coupled to the at least one exposed functional group on the self-assembled monolayer to produce a surface with enhanced cell-adhesive properties.
Owner:BECTON DICKINSON & CO +1

Capillary perfused bioreactors with multiple chambers

A bioreactor for cultivating living cells in a liquid medium. In one embodiment of the present invention, the bioreactor includes a first substrate having a first surface, an opposite second surface and edges. The bioreactor further includes a second substrate having a first surface and an opposite second surface, defining a cavity with a bottom surface, where the bottom surface is located therebetween the first surface and the second surface. The first surface of the first substrate is received by the second surface of the second substrate to cover the cavity so as to form a channel for receiving cells and a liquid medium. In forming the bioreactor, the channel is sized to allow the growth of a layer of cells on a biocompatible coating layer and a flow of liquid in the channel. The flow of liquid is controlled so as to provide a known shear force to the layer of cells. The flow of liquid can be further controlled so as to provide an environment that simulates a vascular space in the channel.
Owner:VANDERBILT UNIV

Synthesis and characterization of biodegradable cationic poly(propylene fumarate-co-ethylene glycol) copolymer hydrogels modified with agmatine for enhanced cell adhesion

A cross-linkable monomer comprises a fumaric acid functional group having a first end and a second end, a first spacer group affixed to said first end and comprising at least repeating unit, a first terminal group affixed to said first spacer group, a second spacer group affixed to said second end and comprising at least one ethylene glycol repeating unit, and a second terminal group affixed to said second spacer group. A hydrogel formed by cross-linking the present monomer and a method for making the monomer. A method for forming a hydrogel, comprises the steps of a) synthesizing a copolymer of poly(propylene fumarate) (PPF) and poly(ethylene glycol (PEG) so as to produce P(PF-co-EG), b) synthesizing a PEG-tethered fumarate (PEGF), c) coupling agmatine sulfate to the PEGF to produce PEGF modified with agmatine (Agm-PEGF), and d) cross-linking the P(PF-co-EG) from step a) with Agm-PEGF from step c).
Owner:RICE UNIV

Capillary perfused bioreactors with multiple chambers

A bioreactor for cultivating living cells in a liquid medium. In one embodiment of the present invention, the bioreactor includes a first substrate having a first surface, an opposite second surface and edges. The bioreactor further includes a second substrate having a first surface and an opposite second surface, defining a cavity with a bottom surface, where the bottom surface is located therebetween the first surface and the second surface. The first surface of the first substrate is received by the second surface of the second substrate to cover the cavity so as to form a channel for receiving cells and a liquid medium. In forming the bioreactor, the channel is sized to allow the growth of a layer of cells on a biocompatible coating layer and a flow of liquid in the channel. The flow of liquid is controlled so as to provide a known shear force to the layer of cells. The flow of liquid can be further controlled so as to provide an environment that simulates a vascular space in the channel.
Owner:VANDERBILT UNIV

Fine-granulometry fungal extract chitine-glucane

The present invention relates to a chitin-glucan copolymer in the form of micrometric particles.The present invention in particular provides a composition containing a chitin-glucan copolymer in the form of micrometric particles for the preparation of cosmetic compositions, and in particular dermatological or dermocosmetic compositions.In particular, the present invention relates to a cosmetic composition for face or body care, such as hydrating, firming or smoothing the skin, and exercising an anti-aging effect, including an anti-wrinkle effect.The purpose of the invention is also to provide a porous material that can for example be used in tissue engineering or cell culture, or that can be used as a material in the cosmetics or pharmaceutical industry.
Owner:KITOZYME

Title inhibitors of urokinase

Novel inhibitors of urokinase are provided which have an arginine or arginine mimic aldehyde or an arginine ketoamide group at P1. These compounds are useful in vitro for monitoring plasminogen activator levels and in vivo in treatment of conditions which are ameliorated by inhibition of or decreased activity of urokinase.
Owner:DENDREON PHARMA INC

Agent for improving cancer cell adhesiveness

A polymer comprising a constitutional unit represented by the following formula (1) is useful because when the polymer is applied to a surface of a cancer cell enrichment filter, adhesiveness of cancer cells to the filter surface can be improved so that an enrichment ratio of the cancer cells can be improved. In the formula (1), R1 is a hydrogen atom or a methyl group, R2 is a methyl group or an ethyl group and m is 1 to 3.
Owner:HITACHI CHEM CO LTD +1

Alginate complex gel stent material constructed based on homogeneous phase crosslinking and layer-by-layer self-assembly technology and preparation method thereof

The invention relates to a gel material, in particular to an alginate complex gel stent material constructed based on homogeneous phase crosslinking and layer-by-layer self-assembly technology and a preparation method thereof, and belongs to the technical field of tissue engineering. Alginate gel is prepared with an HAP / GDL compound as an endogenous crosslinking agent, wherein the mole ratio of HAP to GDL is 1:10, and meanwhile, it is determined that the mole ratio of the Ca element in the HAP to -COOH in sodium alginate (SA) is 0.18-0.36; afterwards, chitosan (CS) with positive electricity and B-type gelatin (GT) (collagen or sericin) with negative electricity are alternately deposited on the surface of the alginate gel through the electrostatic effect; and finally, the GT (collagen or sericin) on the outermost layer is subjected to covalent crosslinking through an EDC / NHS mixture, and therefore an alginate complex gel stent with homogeneous phase crosslinking is prepared.
Owner:HAINAN NORMAL UNIV

Implant with surface structure

An implant with a surface structure on at least a portion of a surface of the implant, wherein the surface structure is selected to facilitate, improve and enhance ingrowth characteristics of the implant. A method of providing an implant with a selected surface structure is encompassed.
Owner:ROCHE DIAGNOSTICS INT

Hydrogel-forming composition comprising natural and synthetic segments

A hydrogel composition is formed from a natural polymer derivative having a plurality of cross-linkable units depending therefrom, and a synthetic polymer derivative having a plurality of cross-linkable units depending therefrom, said natural and synthetic polymer derivatives having hydrolysable units disposed between the polymer backbone of said derivative and at least some of said cross-linkable units. The use of a combination of natural and synthetic polymers provides for biodegradability of the hydrogel, along with mechanical properties such as strength and elasticity.
Owner:ZIMMER ORTHOBIOLOGICS

Method for surface inclusions detection, enhancement of endothelial and osteoblast cells adhesion and proliferation, sterilization of electropolished and magnetoelectropolished nitinol surfaces

InactiveUS20120093944A1Enhancement of endothelialEnhancement of osteoblast cell adhesionSuture equipmentsInorganic active ingredientsOsteoblast adhesionElectrolysis
The method for surface inclusions detection, enhancement of endothelial and osteoblast cells adhesion and proliferation and sterilization of electropolished and magnetoelectropolished Nitinol implantable medical device surfaces uses an aqueous solution of chemical compounds containing halogenous oxyanions as hypochlorite (ClO−) and hypobromite (BrO−) preferentially 6% sodium hypochlorite (NaClO).
Owner:ROKICKI MARGARET

Method of cryopreservation of stem cell-derived retinal pigment epithelial cells on polymeric substrate

Disclosed herein are methods and compositions for the cryopreservation of stem cells, such as stem-cell derived retinal pigment epithelial cells, that have been seeded onto and cultured on a substrate, such as a polymeric substrate. Such cryopreserved stem cells are useful for cell therapies, such as treatment of ocular damage or disease.
Owner:UNIV OF SOUTHERN CALIFORNIA

Tube with modified inner wall surface using plasma and a preparation method thereof

The present invention relates to a preparation method of a tube and a transplantable polymer tube prepared by such method, which includes modifying the inner surface of a tube using plasma. A preparation method of a tube may include preparing a tube, modifying the inner surface of the tube using microplasma so as to have reactivity, forming a thin film layer on the modified surface of the tube to prevent aging or impart adhesiveness, and modifying the surface of the thin film layer using microplasma so as to enhance cell adhesion thereon.
Owner:RES & BUSINESS FOUND SUNGKYUNKWAN UNIV

Compounds and methods for modulating functions of nonclassical cadherins

InactiveUS7476509B2Inhibiting endometriosisEnhancing inhaled compound deliveryBiocideCell receptors/surface-antigens/surface-determinantsCell adhesionAdhesion process
Modulating agents and methods for enhancing or inhibiting nonclassical cadherin-mediated functions, such as atypical or desmosomal cadherin-mediated functions, are provided. The modulating agents comprise at least a tryptophan-containing cell adhesion recognition sequence of an atypical and / or desmosomal cadherin, a conservative analogue or peptidomimetic thereof, or an antibody or fragment thereof that specifically binds to such a cell adhesion recognition sequence. Modulating agents may additionally comprise one or more cell adhesion recognition sequences recognized by cadherins and / or other adhesion molecules. Such modulating agents may, but need not, be linked to a targeting agent, pharmaceutically active substance and / or support material.
Owner:ADHEREX TECH

A method to enhance wound healing using silk-derived protein

Described herein are methods of enhancing wound healing using silk-derived proteins (SDP), including low molecular weight SDP fragments. Also described are compositions for the treatment of wounds, including corneal wounds, skin wounds, surgical incisions, burns, and skin ulcers, comprising SDP fragments, including low molecular weight SDP fragments.
Owner:SILK TECH +1

Compositions and methods for the treatment of skin diseases

PendingUS20210395775A1Low cytotoxicityEffectively transducing mammalian cellConnective tissue peptidesPeptide/protein ingredientsDiseaseLaminin
The present disclosure provides recombinant nucleic acids comprising one or more polynucleotides encoding a laminin polypeptide (e.g., a human laminin polypeptide) and / or a filaggrin polypeptide (e g , a human filaggrin polypeptide); viruses comprising the recombinant nucleic acids; compositions and formulations comprising the recombinant nucleic acids and / or viruses; methods of their use (e.g., for the treatment of Junctional Epidermolysis Bullosa); and articles of manufacture or kits thereof.
Owner:KRYSTAL BIOTECH INC

Plasma protein concentrate for cell delivery in regenerative applications

The invention is directed to concentrating autologously-derived plasma, using the concentrated plasma fluid to dilute the patient's cells and applying the combination of concentrated fluid with cells at a site of pathology or mixing the combination of concentrated fluid with cells with a particulate material like a bone void filler prior to placing the mixture at a site of pathology.
Owner:SPINESMITH PARTNERS
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products